INAB vs. HCWB, SGTX, ORPH, TTOO, ENLV, OTLK, VCXB, XFOR, CRDL, and KOD
Should you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include HCW Biologics (HCWB), Sigilon Therapeutics (SGTX), Orphazyme A/S (ORPH), T2 Biosystems (TTOO), Enlivex Therapeutics (ENLV), Outlook Therapeutics (OTLK), 10X Capital Venture Acquisition Corp. III (VCXB), X4 Pharmaceuticals (XFOR), Cardiol Therapeutics (CRDL), and Kodiak Sciences (KOD). These companies are all part of the "medical" sector.
HCW Biologics (NASDAQ:HCWB) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment.
3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 49.9% of HCW Biologics shares are held by insiders. Comparatively, 15.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
IN8bio has a net margin of 0.00% compared to IN8bio's net margin of -697.53%. IN8bio's return on equity of -146.76% beat HCW Biologics' return on equity.
IN8bio has a consensus price target of $10.00, suggesting a potential upside of 740.34%. Given HCW Biologics' higher probable upside, analysts plainly believe IN8bio is more favorable than HCW Biologics.
IN8bio received 14 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 68.97% of users gave IN8bio an outperform vote.
HCW Biologics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500.
HCW Biologics has higher revenue and earnings than IN8bio. HCW Biologics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, HCW Biologics and HCW Biologics both had 2 articles in the media. IN8bio's average media sentiment score of 1.43 equaled HCW Biologics'average media sentiment score.
Summary
HCW Biologics beats IN8bio on 8 of the 14 factors compared between the two stocks.
Get IN8bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
